Effect of Age on Survival in Patients with Cervical Cancer: Age and Survival in Cervical Cancer

Hatim  M. Al-Jifree; Ahmad Alwazzan; Sara  Aljuaid; Wejdan  Balubaid

doi:10.54393/pjhs.v4i02.622

Authors

Hatim M. Al-Jifree Department of Oncology, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
Ahmad Alwazzan Department of Obstetrics and Gynecology, King Abdulaziz University, Jeddah, Saudi
Sara Aljuaid Department of Oncology, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
Wejdan Balubaid Department of Oncology, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia

DOI:

https://doi.org/10.54393/pjhs.v4i02.622

Keywords:

Cervical Cancer, Survival, Age, Prognostic Factors, Lymph Node, Hemoglobin

Abstract

Cervical cancer survival rates depend on several factors, such as the stage of the cancer, age of the patient, and overall health status. However, early detection through regular screening and prompt treatment can significantly increase the chances of survival. Objectives: To determine the effects of age and other prognostic factors on survival in patients with cervical cancer. Methods: The medical records of 142 patients with cervical cancer were retrospectively reviewed. All patients were diagnosed by biopsy between January 2000 and December 2012 at the Princess Norah Oncology Center of King Abdul Aziz Medical City (Jeddah, Saudi Arabia). Kaplan-Meier survival curves and log-rank tests were used to compare groups. Results: The mean age at diagnosis was 51.77 ± 13.36 years (range, 28–96 years). The 1-year survival rates for each age group were as follows: < 30 years, 100%; 30–54 years, 83.9%; 55–65 years, 72.2%; and > 65 years, 73.3%. By contrast, the 5-year survival rates (0%, 38.5%, 30.8%, and 33%, respectively) were much lower. No significant differences in survival outcomes were identified among the age groups. Low mean hemoglobin levels during treatment were associated with poor survival rates. The mean hemoglobin level for all patients was 14.22 ± 16.28 mg/dL. Conclusions: Survival outcomes in patients with cervical cancer were not influenced by age at diagnosis. It will be necessary to perform systematic reviews of multiple studies on this topic to come to a more definitive conclusion.

References

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA: A Cancer Journal for Clinicians. 2011 Mar; 61(2): 69-90. doi:10.3322/caac.20107.

Anton-Culver H, Bloss JD, Bringman D, Lee-Feldstein A, Disaia P, Manetta A. Comparison of Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: A Population-Based Epidemiologic Study. American Journal of Obstetrics and Gynecology. 1992 May; 166(5): 1507-14. doi: 10.1016/0002-9378(92)91627-M.

Howell E, Chen YT, Moradi M, Concato J. Cervical Cancer Practice Patterns and Appropriateness of Therapy. American Journal of Obstetrics and Gynecology. 2000 Aug; 183(2): 407-13. doi: 10.1067/mob.2000.105939.

Bjørge T, Thoresen SØ, Skare GB. Incidence, Survival and Mortality in Cervical Cancer in Norway, 1956–1990. European Journal of Cancer. 1993 Jan; 29(16): 2291-7. doi: 10.1016/0959-8049(93)90224-4.

Balducci L. Geriatric Oncology: Challenges for the New Century. European Journal of Cancer. 2000 Sep; 36(14): 1741-54. doi: 10.1016/S0959-8049(00)00169-6.

Free K, Roberts S, Bourne R, Dickie G, Ward B, Wright G, et al. Cancer of the Cervix—Old and Young, Now and Then. Gynecologic Oncology. 1991 Nov; 43(2): 129-36. doi: 10.1016/0090-8258(91)90058-D.

Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R. Screening for Cervical Cancer: A Systematic Review and Meta-Analysis. Systematic Reviews. 2013 Dec; 2: 1-4. doi: 10.1186/2046-4053-2-35.

Alghamdi MA. Polymorphism of Selected Genes Coding for Xenobiotic-Metabolizing Enzymes and Susceptibility to Colorectal Cancer in a Saudi Population. Journal of King Abdulaziz University. 2015; 26(1): 17-26. doi: 10.4197/Met. 26-1.2.

Gospodarowicz M, Mackillop W, O'sullivan B, Sobin L, Henson D, Hutter RV, et al. Prognostic Factors in Clinical Decision Making: the Future. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2001 Apr; 91(S8): 1688-95. doi: 10.1002/1097-0142(20010415)91:8+%3C1688::AID-CNCR1184%3E3.0.CO;2-7.

Winter WE, Maxwel GL, Tian C, Sobel E, Rose GS, Thomas G, et al. Association of Hemoglobin Level with Survival in Cervical Carcinoma Patients Treated with Concurrent Cisplatin and Radiotherapy: a Gynecologic Oncology Group Study. Gynecologic Oncology. 2004 Aug; 94(2): 495-501. doi: 10.1016/j.ygyno.2004.04.008.

Wagner AE, Pappas L, Ghia AJ, Gaffney DK. Impact of Tumor Size on Survival in Cancer of the Cervix and Validation of Stage IIA1 and IIA2 Subdivisions. Gynecologic Oncology. 2013 Jun; 129(3): 517-21. doi: 10.1016/j.ygyno.2013.03.008.

Federico C, Alleyn J, Dola C, Tafti S, Galandak J, Jacob C, et al. Relationship Among Age, Race, Medical Funding, and Cervical Cancer Survival. Journal of the National Medical Association. 2010 Mar; 102(3): 199-205. doi: 10.1016/S0027-9684(15)30526-5.

Ioka A, Ito Y, Tsukuma H. Factors Relating to Poor Survival Rates of Aged Cervical Cancer Patients: A Population-Based Study with the Relative Survival Model in Osaka, Japan. Asian Pacific Journal of Cancer Prevention. 2009 Jan; 10(3): 457-62.

Brun JL, Stoven-Camou D, Trouette R, Lopez M, Chene G, Hocké C. Survival and Prognosis of Women with Invasive Cervical Cancer According to Age. Gynecologic Oncology. 2003 Nov; 91(2): 395-401. doi: 10.1016/S0090-8258(03)00501-8.

Delaloye JF, Pampallona S, Coucke PA, De Grandi P. Younger Age as a Bad Prognostic Factor in Patients with Carcinoma of the Cervix. European Journal of Obstetrics & Gynecology and Reproductive Biology. 1996 Feb; 64(2): 201-5. doi: 10.1016/0301-2115(95)02290-2.

Robertson D, Fedorkow DM, Stuart GC, McGregor SE, Duggan MA, Nation G. Age is Prognostic Variable in Cervical Squamous Cell Carcinoma. European Journal of Gynaecological Oncology. 1993 Jan; 14(4): 283-91.

Dattoli MJ, Gretz HF, Beller U, Lerch IA, Demopoulos RI, Beckman EM, et al. Analysis of Multiple Prognostic Factors in Patients with Stage IB Cervical Cancer: Age as a Major Determinant. International Journal of Radiation Oncology* Biology* Physics. 1989 Jul; 17(1): 41-7. doi: 10.1016/0360-3016(89)90368-4.

Poka R, Juhász B, Lampé L. Cervical Cancer in Young Women: A Poorer Prognosis? International Journal of Gynecology & Obstetrics. 1994 Jul; 46(1): 33-7.

Brewster WR, DiSaia PJ, Monk BJ, Ziogas A, Yamada SD, Anton-Culver H. Young Age as a Prognostic Factor in Cervical Cancer: Results of a Population-Based Study. American Journal of Obstetrics and Gynecology. 1999 Jun; 180(6): 1464-7. doi: 10.1016/S0002-9378(99)70038-4.

Tharavichitkul E, Pinitpatcharalerd A, Lorvidhaya V, Kamnerdsupaphon P, Pukanhaphan N, Sukthomya V, et al. Impact of Incomplete Plan to Treatment Results of Concurrent Weekly Cisplatin and Radiotherapy in Locally Advanced Cervical Cancer. Journal of Radiation Research. 2011 Jan; 52(1): 9-14. doi: 10.1269/jrr.10021.